The One to Beat | GenomeWeb

The One to Beat

Matthew Herper at Forbes lays the credit for the growth of Illumina and next-generation sequencing at the feet of Jay Flatley, the company's chief executive officer. Since 2008, under Flatley's guidance, Illumina's sales have increased nearly 150 percent to $1.42 billion, Herper says, while its stock has shot up some 617 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Changes Ahead

What About the Moon?

'Really?'

Market Creator

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.